Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment September 5, 2019 Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment 65 Percent of Patients Remained on Active Surveillance for More than Four Yea... Continue Reading
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy May 9, 2019 New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy New Study Finds Approximat... Continue Reading
EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer April 30, 2019 [vc_row][vc_column][vc_column_text el_class=" text-corporate"] EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Br... Continue Reading
EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer December 19, 2018 EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer NICE Decision is a Major Milestone in Expanding Access to Patient... Continue Reading
Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer December 7, 2018 Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWS... Continue Reading
Myriad Announces Important New Data for Its EndoPredict® Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium December 7, 2018 EndoPredict is the Only Test to Answer Three Critical Questions: Risk of Breast Cancer Recurrence, Benefits of Chemotherapy and Who Can Forgo Extended Endocrine... Continue Reading